VJHemOnc is committed to improving our service to you

Share this video  

VJHemOnc is committed to improving our service to you

ISA 2022 | ISA highlights: anti-fibril agents & AT-01

Vaishali Sanchorawala, MD, Boston University School of Medicine, Boston, MA, discusses her highlights from this year’s ISA meeting, sharing her excitement for advances in treatments for amyloidosis including novel anti-fibril strategies, and commenting on AT-01, an investigational pan-amyloid imaging agent. This interview took place at the 2022 International Symposium on Amyloidosis (ISA) held in Heidelberg, Germany.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Disclosures

Takeda: Research Funding; Celgene: Research Funding; Prothena: Membership on an entity’s Board of Directors or advisory committees, Research Funding; Caelum: Membership on an entity’s Board of Directors or advisory committees, Research Funding; Janssen: Honoraria, Membership on an entity’s Board of Directors or advisory committees, Research Funding; Abbvie: Membership on an entity’s Board of Directors or advisory committees; Regeneron: Membership on an entity’s Board of Directors or advisory committees; Proclara: Membership on an entity’s Board of Directors or advisory committees; Pfizer: Honoraria; Karyopharm: Research Funding.

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter